Last reviewed · How we verify
Standardized antihypertensive therapy
Standardized antihypertensive therapy reduces blood pressure through one or more established pharmacological classes of antihypertensive agents.
Standardized antihypertensive therapy reduces blood pressure through one or more established pharmacological classes of antihypertensive agents. Used for Hypertension management.
At a glance
| Generic name | Standardized antihypertensive therapy |
|---|---|
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This represents a standardized treatment protocol rather than a single drug entity, typically combining agents from classes such as ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, or diuretics. The mechanism depends on the specific agents included in the protocol, which work through various pathways including vasodilation, reduced cardiac output, or decreased fluid volume to lower blood pressure.
Approved indications
- Hypertension management
Common side effects
- Hypotension
- Dizziness
- Fatigue
- Cough (if ACE inhibitor-containing)
- Hyperkalemia (if ACE inhibitor or ARB-containing)
Key clinical trials
- REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription (NA)
- "Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2) (NA)
- A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease (NA)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Electroacupuncture on Treating Cancer-related Depression (NA)
- China Rural Hypertension Control Project (NA)
- bpMedManage: Digital Technology to Support Adherence to Hypertension Medications (NA)
- Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: